The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
Binary combinations of cisplatin and the 5-HT3 antagonist, BRL 43694, have been used to treat both conventional mice bearing either L1210 leukaemia or ADJ/PC6 plasmacytoma and nude mice xenografted with a human ovarian carcinoma (HX/110). In no case was there evidence for antagonism by the antiemetic of the antitumour properties of cisplatin.
Goddard
P M
PM
Drug Development Section, Institute of Cancer Research, Sutton, Surrey, U.K.
Jones
M
M
Pollard
L A
LA
Valenti
M R
MR
Harrap
K R
KR
D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D017829:Granisetron; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010954:Plasmacytoma / Q000188:drug therapy; D011720:Pyrazoles / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*
D002945:Cisplatin; D017829:Granisetron; D007191:Indazoles; D011720:Pyrazoles; D012702:Serotonin Antagonists